Immunome, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 106.81 million compared to USD 36.9 million a year ago. Basic loss per share from continuing operations was USD 5.38 compared to USD 3.09 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.15 USD | -2.57% | +3.63% | +41.59% |
May. 31 | Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target | MT |
May. 21 | Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.59% | 933M | |
+19.33% | 125B | |
+13.95% | 109B | |
-3.53% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.62% | 16.64B | |
+0.99% | 13.45B | |
+21.79% | 11.32B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023